Sacubitril-valsartan in Patients With Heart Failure.

Summary

The aim of this study is to evaluate the safety and efficacy of Sacubitril -Valsartan in patients with heart failure.

Eligibility

Inclusion Criteria:

* Age ≥ 18 years old for both genders.
* LV ejection fraction (LVEF) ≤40%.
* Heart failure patients with NYHA grade II-IV.

Exclusion Criteria:

1. CKD with GFR \< 20 ml/min/1.73
2. Serum potassium \< 5.5 mmol / L.
3. Pregnant or lactating women
4. Active infection.
5. Congenital heart disease.
6. Autoimmune disorders or connective tissue disorders.
7. Severe hepatic dysfunction.

Conditions2

Interventions2

Related trials

• Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy — University of Edinburgh
• Sacubitril/Valsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction — Kafrelsheikh University
• Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM) — Silesian Centre for Heart Diseases
• The Effect of Sacubitril/valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients with Ischemic Heart Failure with Mid-range Ejection Fraction — John Paul II Hospital, Krakow
• Treatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease — China National Center for Cardiovascular Diseases
• Vericiguat in Decompensated Cardiac Failure: Clinical Insights on Addition to Guidelines Derived Medical Therapy-VERCIG Trial — Khawaja Danish Ali
• Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts — Heart Center Research, LLC
• Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) Study — The Cleveland Clinic

Browse More Trials